Metraipolis › archive › dc_4b036942eaa4

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer — Europe PMC PMID:41564819

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41564819
DOI
10.1016/j.esmoop.2025.106052
License (as archived)
solo-consultazione
Archived
2026-11-06T16:33:06.525Z
SHA-256 of the archived text
43f45272d2ef26628b696203ed769e188ca25e556a9b62eccc05f61cc4f83114
Stable URL of this page
https://metraipolis.com/documento/dc_4b036942eaa4

How to cite

Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer — Europe PMC PMID:41564819 — Europe PMC (en), https://europepmc.org/article/MED/41564819 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4b036942eaa4 (Metraipolis archive dc_4b036942eaa4, sha256 43f45272d2ef26628b696203ed769e188ca25e556a9b62eccc05f61cc4f83114)
BibTeX
@misc{dc4b036942eaa4,
  title = {Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer — Europe PMC PMID:41564819},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41564819},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4b036942eaa4; sha256 43f45272d2ef26628b696203ed769e188ca25e556a9b62eccc05f61cc4f83114},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41564819. Agents can read the archived copy with the MCP tool read_document.